A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy.
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2016
At a glance
- Drugs Apitolisib (Primary) ; Everolimus
- Indications Renal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ROVER
- Sponsors Genentech
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2014 Status changed from active, no longer recruiting to recruiting, as per ClinicalTrials.gov record.